{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 29,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide outlines a non-inferiority trial design comparing oral MAT2203 to IV LAMB/SoC.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/16",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing initial treatment, randomization, and step-down treatment arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35180fe2-6dec-4971-b814-f0da29c7f8fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.27,
        "x": 0.36,
        "y": 0.71
      },
      "kind": "list",
      "text": "PRIMARY ENDPOINT: All-Cause Mortality at Study Day 42. SECONDARY ENDPOINTS: Global response to treatment, All-cause mortality at 84 days, Safety and tolerability, Pharmacoeconomic impact",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42967bcf-3714-42c4-a4e9-2cd8f3b4e0d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.33,
        "x": 0.02,
        "y": 0.75
      },
      "kind": "list",
      "text": "Treatment of IA in patients with LIMITED TREATMENT OPTIONS: Fungal pathogen not susceptible to azoles, Risk for toxicity or drug-drug interactions with azoles, Other clinical contraindications for azole use",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bc290e5-bd6a-4da8-be0c-000dc4637672",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.34,
        "x": 0.64,
        "y": 0.71
      },
      "kind": "list",
      "text": "KEY SECONDARY SUPERIORITY SAFETY ENDPOINT: Treatment discontinuation or dose adjustment due to treatment-related toxicity (Renal, Hypokalemia, Infusion-related, Hepatic, DDI, GI, etc.)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68971c87-a1c4-42d9-9423-8a6841cc1fb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is comparable to (noninferior) SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive treatment with a mold-active azole and have limited alternative treatment options",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "780f8021-2f16-41b6-aacf-bbd184913bfa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Patients will be randomized 2:1 to receive either oral MAT2203 (Experimental Arm) or continued IV LAMB followed by Standard of Care (Comparator Arm)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db1b81a1-a4ce-4242-8421-090428f0133f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "* Phase 3 trial start dependent on securing partnership(s) or non-dilutive government funds",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5c16996-4d27-4d7f-ae3a-ddfb4345b135",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (IA) (the “ORALTO” Trial)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d0b170f-1817-4eaa-939e-6e605c1b780b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "f8cf8bcf-1213-492a-b8a5-461dfbe4bf7b",
      "evidence": "The slide presents a clear structure with a title, study design, and key endpoints, which aligns with the SCQA framework.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c020a8cd-19c2-4f66-b8fd-1a6de00826c3",
      "evidence": "The regulatory and development strategy for MAT2203 and the LNC platform are presented",
      "position": 2,
      "objective": "What are the near-term milestones and potential for growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}